Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-HER2 CAR-M in Advanced Gastric Cancer
NCT06224738Phase 1Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-0508 in gastric cancer (GC), sponsored by Hangzhou First People's Hospital. Primary endpoint: Adverse effects at 28 days. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
CT-0508
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06224738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06224738.